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Maedi-visna virus (MVV) is a lentivirus of sheep causing inflammation in many organs, primarily the lungs 
and CNS. HIV and SIV also belong to the lentivirus genus of retroviruses. MVV and HIV have many features 
in common, including genome organization, mode of virus replication, virus-host interaction and latency. Both 
viruses infect cells of the monocyte/macrophage lineage, but the main difference in cell tropism is that, whereas 
HIV infects T lymphocytes, MVV does not. Here, the molecular biology, cell tropism and pathogenesis of MVV 
are reviewed and some of the similarities as well as the dissimilarities between MVV and HIV are discussed. 
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Mæði-visnuveira og HIV: Margt er líkt með skyldum.
Mæði-visnuveira sýkir kindur og veldur aðallega lungnabólgu (mæði) og heilabólgu (visnu).  Veiran er lentiveira 
og er náskyld alnæmisveirunni HIV. Veirurnar eiga margt sameiginlegt, svo sem skipulag erfðaefnis, virkni og 
gerð veirupróteina, fjölgunarferli, viðbrögð hýsils við sýkingu og dvalasýkingu, sem hýsillinn losnar aldrei við. 
Báðar veirur sýkja frumur ónæmiskerfisins; mæði-visnuveira sýkir átfrumur, en HIV sýkir bæði átfrumur og 
T-eitilfrumur. Í þessari yfirlitsgrein verða ýmis líkindi með þessum veirum reifuð. 




Maedi (an Icelandic word for “breathlessness”) 
and visna (meaning wasting) are diseases that 
were brought to Iceland in 1933 with imported 
sheep of the Karakul breed. These diseases had 
gone mostly unnoticed in many countries, but 
the Icelandic sheep, which had been in almost 
total isolation in Iceland for over a thousand 
years, proved to be very susceptible to them. 
Epidemiological studies suggest that of the 20 
sheep that were imported, two were healthy 
carriers, one giving rise to an epizootic of 
maedi in the northern part of the country, the 
other causing an epizootic of both maedi and 
visna in the west part of the country.  Due to the 
long preclinical period, the diseases had spread 
unnoticed to many flocks when first recognized 
6-7 years after the importation (Palsson 1976). 
The diseases were described by Sigurdsson 
and co-workers (Sigurdsson 1954a, 1954b, 
Sigurdsson et al. 1952, Sigurdsson et al. 1953, 
Sigurdsson et al. 1957). Serological studies and 
transmission experiments revealed that visna 
and maedi were manifestations of infection 
with the same virus in different organs, thus 
giving rise to the present name, maedi-visna 
virus (MVV) (Thormar and Helgadottir 1965, 
Gudnadottir and Palsson 1967, Gudnadottir & 
Palsson 1965). Other manifestations of an MVV 
infection are mastitis (De Boer et al. 1979) and 
arthritis (Oliver et al. 1981). In his studies of 
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maedi and visna, Sigurdsson noted the long 
incubation time without clinical signs, lasting 
for several months to years, and the protracted 
course after clinical signs appeared, usually 
ending in serious disease or death. He found this 
different from the course of acute infections, 
on the one hand, and chronic infections on the 
other, and proposed the term slow infections 
for this type of infection (Sigurdsson 1954b, 
reviewed by Thormar 2013). 
MVV is a member of the lentivirus 
genus of the retroviridae that derive their 
name from Sigurdsson´s concept of slow 
infections (lentus=slow) (Haase 1975). Ovine 
lentiviruses have been identified worldwide 
and are variously referred to as maedi-visna 
virus (MVV), visna/maedi virus (VMV), ovine 
progressive pneumonia virus (OPPV), and 
ovine lentivirus (OvLV). The lentivirus of goats 
(caprine arthritis encephalitis virus, CAEV) has 
the same genome organization and target organs 
as MVV, and a number of studies have found 
evidence for the occurrence of cross-species 
transmission of MVV and CAEV between 
sheep and goats (Karr et al. 1996,  Leroux et 
al. 1997,  Zanoni 1998). The sheep and goat 
lentiviruses are commonly referred to as small 
ruminant lentiviruses (SRLV). The SRLVs 
are divided into five phylogenetic groups, 
A-E, which are again divided into subgroups. 
The prototype MVV strains are in group A1, 
while the prototype CAEV is in group B1 
(Grego et al. 2007,  Shah et al. 2004).  Other 
lentiviruses are feline immunodeficiency virus 
(FIV), bovine immunodeficiency virus (BIV), 
equine infectious anaemia virus (EIAV), simian 
immunodeficiency viruses (SIV), and human 
immunodeficiency viruses (HIV).
Transmission and clinical signs
During the MVV epizootic in Iceland, the main 
route of transmission was via the respiratory 
tract. In Iceland, sheep are housed in close 
contact during winter, and during summer 
they used to roam freely on common unfenced 
pastures in the mountains. In the autumn 
roundups the sheep were kept by the thousands 
in big collecting folds for 1-3 days while being 
sorted out into their original flocks belonging to 
individual owners. This traditional method of 
sheep farming contributed to the rapid spread 
of the disease (Palsson 1976). Another route 
of transmission is through colostrum and milk 
from mother to offspring (Blacklaws et al. 
2004,  Peterhans et al. 2004). Transmission of 
HIV also occurs between HIV infected mothers 
and newborns, and intrauterine transmission 
seems to be more common in HIV infection 
than in SRLV infection. The main route of 
HIV transmission is through sexual contact and 
although the virus is found in lung fluids, there 
is no evidence that HIV is transmitted by the 
respiratory route (reviewed in B. Blacklaws and 
Harkiss 2010). MVV has been found in semen, 
but there are no reports of sexual transmission 
of MVV (Al Ahmad et al. 2008,  Peterson et al. 
2008). 
Lentiviral diseases of small ruminants are 
characterized by chronic inflammation mostly 
affecting the lungs, brain, mammary glands 
and joints. The organ affected may be a result 
of both the viral strain and host species. The 
lung disease (maedi) was most prevalent 
during the epizootic in Iceland. Because of the 
long silent preclinical phase of the infection, 
clinical signs of maedi were rarely seen in 
animals under 3-4 years of age. The first clinical 
signs were increased laboured breathing and 
lagging behind when the flock was driven. As 
the disease progressed, the respiration at rest 
became gradually more laboured and the sheep 
lost condition.  Coughing is not a prominent 
sign in maedi and is not productive when it 
occurs. This non-febrile disease usually lasted 
for 3-8 months or longer and was always fatal. 
(Thormar 2013, Palsson 1976).    
The clinical signs of visna, a CNS disease, 
were aberration of gait, notably affecting the 
hind quarters. There was a gradually increasing 
weakness of the hind legs progressing to 
paraplegia or almost total paralysis. A general 
loss of condition was often seen and weight 
loss despite a healthy appetite (Pétursson et 
al. 1992). Clinical visna is rarely seen in ovine 
lentivirus infections outside of Iceland, where 
it was predominant in certain flocks where 
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maedi was also found (Pétursson et al. 1992). 
However, regional outbreaks of visna have been 
reported in other countries (Benavides et al. 
2007,  Brodie et al. 1995,  Glaria et al. 2012). 
Mastitis, with diffuse or nodular hardening 
of the udder and reduction of milk production 
was also seen (Cutlip et al. 1985,  Pétursson et 
al. 1992,  van der Molen et al. 1985). In contrast 
to sheep, arthritis is the prominent disease 
manifestation of SRLV in goats (Crawford et 
al. 1980) although mastitis is also common, 
especially in dairy herds. 
Similar to MVV, early targets of HIV 
infection are the CNS and the lungs. The 
lymphoid interstitial pneumonia observed in 
HIV infection is similar to the typical lung 
manifestations in ovine lentiviral infections and 
a large proportion of HIV-infected individuals 
develop encephalitis. HIV infection causes 
immunodeficiency which is not seen in MVV, 
and frequent opportunistic infections in AIDS 
affect the pathological picture and make 
comparisons between the human and ovine 
disease difficult. For a comprehensive review 
see Blacklaws & Harkiss 2010.
Cell tropism 
The lentiviruses are a non-oncogenic genus 
of the retroviridae that infect cells of the 
immune system. Several studies have shown 
that the main target cells of the ovine and 
caprine lentiviruses in vivo are cells of the 
monocyte/macrophage lineage; i.e. monocytes, 
macrophages, dendritic cells and microglial 
cells, T-lymphocytes are not infected. Viral 
replication is restricted until differentiation of 
the monocytes into macrophages (Clements 
et al. 1994, Gendelman et al. 1985, Gorrell et 
al. 1992).  In contrast, HIV replicates both in 
lymphocytes and macrophages. The lentiviruses 
are thus unique among retroviruses in infecting 
non-dividing cells. 
The cell tropism of HIV is largely determined 
by cell receptor usage. The primary cell receptor 
is CD4, and in addition, HIV Env binds to 
chemokine receptors that act as co-receptors for 
the virus, usually CCR5 or CXCR4 (Deng et al. 
1996, Feng et al. 1996). Virus strains that are 
transmitted almost exclusively use CCR5 as a 
co-receptor. These viruses are termed R5 variants 
and can enter both T-cells and macrophages. 
However, most newly transmitted/founder 
viruses require high levels of CD4 for infection, 
and T cells expressing a much higher level of 
CD4 than macrophages are therefore primarily 
infected. As the infection progresses, CXCR4 
(X4) – tropic viral strains emerge, as well as R5 
strains that can infect cells with low levels of 
CD4 and are thus macrophage-tropic (Joseph et 
al. 2015).   
The cellular receptors for the sheep and 
goat lentiviruses have not been identified, but 
there seem to be strain differences in the use 
of receptors. Thus, the Icelandic MVV strains 
KV1772 and K1514 and the British strain EV1 
can enter a variety of cell types from a wide 
range of species, while many MVV strains 
and CAEV are restricted to cells of ruminant 
species (Bruett & Clements 2001,  Gilden et 
al. 1981,  Lyall et al. 2000,  Mselli-Lakhal et 
al. 2000). A number of putative receptors have 
been suggested, among them MHC class II 
(Dalziel et al. 1991), mannose receptor (Crespo 
et al. 2011), a 45 kDa protein that has serine/
threonine kinase activity and a 30 kDa protein 
which is a chondroitin sulphate proteoglycan 
(Barber et al. 2000, Bruett et al. 2000). In this 
connection it is interesting to note that heparan 
sulphate proteoglycans have been implicated 
as attachment receptors for HIV-1 (reviewed in 
Connell & Lortat-Jacob 2013).
Although MVV can enter a variety of cell 
types, replication in vivo is largely restricted 
to macrophages, dendritic cells or microglia in 
the brain (Brodie et al. 1995, Ebrahimi et al. 
2000).  The cell and organ tropism of MVV 
has been shown to be determined at the level of 
transcription (Agnarsdottir et al. 2000, Barros et 
al. 2005, Oskarsson et al. 2007). Transcription 
of the retroviruses is directed by the 5’ long 
terminal repeat (LTR) of the integrated proviral 
DNA. The U3 region of the LTR contains 
the promoter and enhancer regions of the 
virus which are composed of binding sites 
for an array of transcription factors which are 
differently activated in the different cell types 
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(Gabuzda et al. 1989, Hess et al. 1985, 1989). 
However, in some instances it has been shown 
that the LTR is not responsible for cell tropism 
(Blatti-Cardinaux et al. 2016, Mselli-Lakhal, et 
al. 2000). 
During the epizootic in Iceland, it was 
evident that there were strain differences in 
organ tropism, i.e. some virus strains seemed to 
be more neurotropic than others (Andresdottir 
et al. 1998).  We found that a duplication of 
a sequence in the LTR, CAAATG, which 
constitutes an E-box, allowed the virus to grow 
in a variety of sheep cell types, including sheep 
choroid plexus cells. The control was most 
likely at the level of chromatin modification, 
since a difference in promoter activity could 
not be detected in the context of a reporter 
plasmid in transient transfection. This sequence 
was associated with neurotropic strains, which 
indicated that virus strains that can infect the 
cells which comprise the blood-brain barrier, 
that is, endothelial cells or cells of the choroid 
plexus, may be more neuroinvasive than others 
(Oskarsson et al. 2007). Another way of crossing 
the blood-brain barrier is by infected monocytes 
entering the brain, a process that has been called 
the “Trojan horse mechanism” (Peluso et al. 
1985). 
Genes and proteins of MVV and HIV-1
Lentiviruses, like other retroviruses, contain 
their genetic information in positive strand 
RNA molecules (genomic RNA, gRNA). Each 
virion contains two such molecules. The size 
of the RNA molecules of lentiviruses is 9-10 
kilobases, somewhat larger than found in most 
retroviruses. The genome contains the three 
genes coding for the structural and enzymatic 
proteins, gag, pol and env, common to all 
retroviruses, and in addition, various numbers 
of regulatory and accessory genes (Figure 1). 
The gag gene codes for the inner structural 
proteins. The Gag precursor in HIV is a p55 
myristoylated protein which is processed by the 
viral protease to p17 (matrix; MA), p24 (capsid; 
CA), p7 (nucleocapsid; NC) and p6 proteins, 
in addition to two spacer proteins, p2 and p1, 
that flank the NC (see Figure 1). The N-terminal 
myristoylation of Gag increases its affinity for 
membranes and is necessary for HIV and SIV 
budding (Morikawa et al. 1996, Olety & Ono 
2014). However, myristoylation is not required 
for MVV budding, and it is not clear whether the 
MVV Gag precursor requires alternative fatty 
acid modification (e.g. acetylation) or remains 
unmodified (Rafnar et al. 1998). MVV Gag is 
processed to p16 (MA), p25 (CA) and p14 (NC) 
(Vigne et al. 1982).  This sequence of proteins 
in the gag gene is conserved in all retroviruses. 
MA guides Gag to the plasma membrane for 
budding and recruits viral and host factors. In the 
mature virion, MA protein lines the underside 
of the lipid envelope of the virus (reviewed in 
Bell & Lever 2013).  CA forms a cone-shaped 
capsid that is characteristic for the lentiviruses. 
The capsid contains the two RNA molecules of 
the virus as well as associated proteins. The NC 
domain of Gag in MVV contains two zinc finger 
domains (CCHC) which are highly conserved 
among retroviruses (Morcock et al. 2000) and 
selectively bind viral RNA for encapsidation 
into the virion. The RNA is packaged as a 
dimer, and the site of dimer initiation in the 
leader region of MVV RNA has been located 
just upstream of the major splice donor (Monie 
et al. 2005). In general, the packaging signals 
of retroviruses are located in and near the 5‘-
UTR of the gRNA and are several hundred 
bases long (Comas-Garcia et al. 2016). In some 
retroviruses, minimal RNA sequences that are 
sufficient for packaging of heterologous RNA 
have been defined (Adam & Miller 1988,  Banks 
et al. 1998). However, packaging determinants 
have not been characterized fully for most of the 
lentiviruses (Berkowitz et al. 1995, Bjarnadottir 
et al. 2006), although both HIV and MVV RNA 
contain packaging signals located in the 5’ 
region of the genome spanning the major splice 
donor and the Gag initiation codon (Bjarnadottir, 
et al. 2006, Sundquist & Krausslich 2012).   In 
addition to RNA packaging, the mature NC 
protein is thought to assist reverse transcriptase 
in converting the single-strand genomic RNA 
into the double-stranded proviral DNA and to 
chaperone the IN-mediated integration of the 
proviral DNA into the host genome (reviewed 
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in Mori et al. 2015). 
In HIV, the C-terminal 52 aa of the Gag 
precursor constitutes the p6 peptide. The 
p6 contains short domains, called the late 
(L) domains, involved in virus budding and 
incorporation of the accessory protein Vpr into 
the virion (Bell & Lever 2013). A total of three 
different core sequences have been identified as 
essential elements for the L-domain function: 
P(T/S)AP, PPXY and LYPXnL. These sequences 
serve as binding sites for cellular proteins that 
associate or function in the endocytic sorting 
complex required for transport (ESCRT) 
pathway. The p6 of HIV contains two L-domain 
sequences: PTAP and LYPXnL that bind 
TSG101 and ALIX proteins of the ESCRT 
pathway, respectively (Bello et al. 2012). MVV 
contains a PSAP motif at the C-terminus of 
NCp14, and it has been shown that the terminal 
10 aa in MVV NC p14, RVVPSAPPML, can 
functionally replace an analogous late domain 
in Rous sarcoma virus (Xiang et al. 1996). 
The Pol polyprotein is expressed as a Gag-
Pol polyprotein which is produced as a result 
of -1 ribosomal frameshifting in about 5% of 
translation events.  In HIV, this frameshifting 
occurs in a so-called slippery sequence located 
near the 5’ terminus of p6. In MVV the 
ribosomal frameshifting signal is an unusual 
pseudoknot which is well conserved in SRLVs 
(Pennell et al. 2008).  The Gag-Pol polyprotein 
is processed by the viral protease into protease, 
reverse transcriptase (RT), RNaseH, dUTPase 
and integrase (IN).  The reverse transcriptase, 
RNaseH and integrase are functionally well 
conserved between HIV and SRLV as evidenced 
by the similar action of anti-HIV-RT agents 
(Thormar et al. 1995, Thormar et al. 1998) and by 
the conserved structure and function of integrase 
(see a later section for details). However, 
dUTPase is only coded for by the non-primate 
lentiviruses FIV, EIAV, BIV, CAEV and MVV, 
but HIV and SIV do not contain a dUTPase gene. 
The dUTPase hydrolyses dUTP to dUMP and 
PP and thus provides a substrate for thymidylate 
synthase in the major biosynthetic pathway to 
vif































Figure 1. Genome organization of MVV and HIV-1. The HIV-1 map is based on strain HXB2 as shown on 
the Los Alamos HIV database website http://www.hiv.lanl.gov/.  The MVV map is based on the MVV strain 
KV1772 sequence (Andresson et al. 1993).
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TTP. Its activity lowers the dUTP/TTP ratio 
and thus reduces the misincorporation of 
dUTP into DNA, which may induce mutations. 
The dUTPase-deficient FIV and CAEV have 
an increased G-A mutation frequency and 
dUTPase deficient EIAV replicates with slower 
kinetics in macrophages than the wild-type; 
however the effect of deleting the dUTPase gene 
from MVV is subtler. There is no difference in 
pathogenicity, but there is a decreased frequency 
of virus isolations from the lungs (Lerner et al. 
1995,  Lichtenstein et al. 1995,  Petursson et al. 
1998,  Turelli et al. 1997,  Turelli et al. 1996). 
The gene is well conserved and it is likely to 
have an important function, although in some 
SRLV strains it seems to be dispensable (Reina 
et al. 2010).
The envelope (Env) glycoproteins are 
produced as a precursor protein that is cleaved 
by cellular proteases into surface glycoprotein 
(SU; gp120 for HIV, gp135 for SRLV) and 
transmembrane glycoprotein (TM; gp41 for 
HIV, gp46 for SRLV).  The SU harbours 
regions that recognize cellular receptors and 
TM mediates fusion with the cell membrane. 
During virus assembly the SU/TM complex is 
incorporated as heterotrimeric spikes into the 
lipid bilayer of nascent virions (reviewed in 
Checkley et al. 2011). The structure of the Env 
proteins of SRLV and HIV is remarkably similar 
despite limited sequence homology (Hotzel 
and Cheevers 2001, 2003, Malashkevich et al. 
2001).
The three regulatory and auxiliary genes of 
the small ruminant lentiviruses are rev, vif and 
tat/ vpr-like. 
Rev is a regulatory protein, expressed early 
in the infectious cycle, facilitating the transport 
of unspliced and singly spliced RNA molecules 
out of the nucleus (Sargan et al. 1994, Toohey 
& Haase 1994, Vigne et al. 1987). The Rev 
proteins act by binding structured RNA domains 
termed Rev responsive elements (RRE) located 
in the env gene (Malim et al. 1989, Mazarin et 
al. 1990, Tiley et al. 1991). The RREs of HIV 
and MVV are not interchangeable, however 
(Tiley & Cullen 1992). 
Vif (Viral infectivity factor) is essential for 
the replication of the virus in primary cells and 
in vivo (Audoly et al. 1992, Fisher et al. 1987, 
Kristbjornsdottir et al. 2004, Strebel et al. 1987). 
Vif neutralizes APOBEC3 proteins which 
are cellular restriction factors that deaminate 
retroviral single stranded (ss) DNA as it is being 
synthesized (see a later section for details).
The vpr-like gene in SRLV was formerly 
called tat, analogous to the tat gene in HIV, since 
it had some trans-activating effect (Davis and 
Clements 1989, Neuveut et al. 1993, Vigne et 
al. 1987). The Tat proteins of HIV, SIV, BIV and 
EIAV are essential for efficient viral replication 
and transactivate their viral long terminal repeats 
(LTR) strongly upon binding to a TAR sequence 
(Derse et al. 1991, Liu et al. 1992, Viglianti and 
Mullins 1988). MVV, CAEV and FIV do not 
possess a TAR sequence, and the “Tat” protein 
of SRLVs was shown to be a weak transactivator 
(Barros et al. 2005, Sargan and Bennet 1989, 
Villet et al. 2003). MVV Tat acts through AP-1 
and AP-4 binding sites in the LTR by binding 
to Fos and Jun transcription factors (Carruth et 
al. 1994, Gdovin & Clements 1992, Morse et 
al. 1999). Deletion of the gene in CAEV only 
resulted in a modest effect on replication both 
in vitro and in vivo (Harmache et al. 1995).  The 
protein has been found to have characteristics 
more like Vpr (Viral protein R) than Tat in HIV. 
Vpr seems to be a multifunctional protein, but 
its roles in infection are still poorly understood. 
Vpr is incorporated into the virion, indicating a 
role in the early steps of virus replication, and 
it is part of the reverse transcriptase complex 
(RTC) as well as the preintegration complex 
(PIC). Vpr binds to transcription factors, and 
like in MVV, one of them is AP-l. (Varin et al. 
2005). AP-1 and AP-4 have been implicated in 
latency (Duverger et al. 2013, Imai & Okamoto 
2006), and it is interesting to speculate that 
Vpr may have a role in latency. Vpr induces 
cell cycle arrest at the G2 to mitotis (G2/M) 
transition by connecting the DCAF1 adaptor of 
the Cul4A ubiquitin ligase to an unidentified host 
target protein linked to the G2 arrest. It is also 
implicated in apoptosis (reviewed by Guenzel 
et al. 2014).  Like HIV Vpr, the SRLV Vpr-like 
protein induces cell cycle arrest at the G2/M 
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transition, it is incorporated into the virion and 
has a nuclear localization (Rea-Boutrois et al. 
2009, Villet et al. 2003).  
Replication
As in other retroviruses, the two copies of 
maedi-visna virus positive strand RNA are 
reverse transcribed in the cytoplasm of the 
cell.  The discovery by Temin (Mizutani et 
al. 1970) and Baltimore (Baltimore 1970) of 
an enzyme that can copy RNA into DNA was 
soon followed by Thormar who showed that 
MVV also contained an RNA-dependent DNA 
polymerase (Lin & Thormar 1970). Upon 
infection of a cell, the capsid core containing 
the viral RNA and viral enzymes is released 
into the cytoplasm, where it dissociates in an 
orderly fashion, called uncoating. Uncoating 
is a finely tuned process that is regulated by 
cellular proteins; too fast or too late uncoating 
can severely attenuate replication (Forshey et 
al. 2002). There is even evidence to suggest 
that the capsid remains intact until it reaches the 
nucleus (Jacques et al. 2016). In recent years, 
it is becoming clear that the capsid plays an 
important role in multiple steps of the lentiviral 
life cycle and infection (reviewed in Ambrose 
and Aiken 2014,  Yamashita & Engelman 2017). 
The capsid is part of the reverse transcriptase 
complex (RTC). The RTC contains viral RNA, 
reverse transcriptase (RT) and other viral 
and host proteins which have not been fully 
characterized, but MA, CA, NC, IN, Vpr and 
Vif have been reported to be present in the RTC, 
and although purified RT can carry out reverse 
transcription in vitro, mutations in most of these 
genes impede reverse transcription in infected 
cells (reviewed in Hu & Hughes 2012). The RT 
makes use of lysine tRNAs to initiate a DNA 
copy of the RNA genome, the RNA is degraded, 
and a second strand of DNA is produced. This 
viral DNA contains duplications of both the 5’ 
and 3’ ends of the genome, forming long terminal 
repeats (LTRs) characteristic of retroviral DNA 
provirus.
The RT lacks proof-reading activity and as a 
result the mutation rate is 105- to 106-fold higher 
than the mutation rates of DNA polymerases 
(Dougherty & Temin 1986), contributing to 
the high genetic variability of the retroviruses 
(Coffin 1992). In addition, recombination 
contributes to the generation of genetic diversity 
of the retroviruses. Recombination results from 
RT template switching between the two RNA 
molecules. SRLV recombination both in vitro 
and in vivo has been reported (Andresdottir 
2003, Pisoni et al. 2007, Ramirez et al. 2011).       
The RTC is transported towards the nucleus 
via the microtubule network (McDonald et al. 
2002). When reverse transcription is completed, 
the RTC transforms into a preintegration 
complex (PIC) which is transported into the 
nucleus. The PIC has to be transported through 
the nuclear pore complexes (NPC) by a not yet 
fully understood mechanism. In addition to the 
newly synthesised DNA, the PIC is composed 
of cellular and viral proteins, among these 
are IN, MA and Vpr, all harbouring nuclear 
localization signals (NLS). In addition, although 
CA does not possess an NLS, it is believed to 
mediate nuclear import (reviewed in Matreyek 
& Engelman 2013).      
In order to replicate in the cell, retroviruses 
have to integrate their genome into the host 
chromosomes. This is achieved by the virus-
encoded integrase protein, which is conserved 
among all retroviruses. The retroviral integrase 
has to carry out two consecutive reactions; 
hydrolysis of a phosphodiester bond at either 
viral DNA (vDNA) end, removing a di- or 
trinucleotide, liberating 3’-hydroxyl groups 
attached to invariant 5’-CA-3’ dinucleotides, 
and cutting the host DNA in a staggered fashion, 
simultaneously joining both 3’ vDNA ends to 
the host DNA resulting in repeated sequences 
of 4-6 bp flanking the inserted viral DNA 
(reviewed in Lesbats et al. 2016). A multimer 
of integrase molecules complexed with vDNA 
is referred to as the intasome.  HIV-1 integrase 
is an extremely difficult protein to work with, 
and in structural analysis it has been necessary 
to introduce hyperactive and/or solubilizing 
mutations, which dramatically change the 
properties of the protein (Ballandras-Colas 
et al. 2017). However, MVV integrase lends 
itself nicely for structural studies as a wild-
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type protein, and using MVV integrase as a 
model for lentiviruses, Ballandras-Colas et al. 
were able to visualize the functional intasome 
at 4.9 angstrom resolution using cryo-electron 
microscopy. The MVV intasome contains 
sixteen integrase subunits with a tetramer-of 
tetramer architecture, interacting with the two 
vDNA ends. This is a more complex intasome 
structure than that of other retroviruses that are 
known, where the PFV (foamy virus) intasome 
contains one tetramer and alpha- and beta-
retroviruses have an intasome composed of two 
integrase tetramers. The structure of the MVV 
intasome can explain much previous data on 
the HIV-1 intasome structure, where the lack of 
structural information on the HIV-1 intasome 
has hampered drug development targeting HIV-
1 integration (Ballandras-Colas et al., 2017).
The target sites of MVV integrase are as those 
of other lentiviral integrases, predominantly in 
actively transcribed genes, whereas the gamma-
retroviruses favour transcriptional start sites 
and enhancer regions (Serrao et al. 2015). The 
alpha-, beta- and delta-retroviruses display more 
random distributions.  The target DNA repeat 
sequence of MVV integrase is 6 bp, more like 
mouse mammary tumour virus (MMTV) and 
Rous sarcoma virus (RSV) than HIV-1 and 
other lentivirus integrases that yield a 5 bp target 
site duplication. 
The retroviruses have been considered 
promising candidates for gene therapy 
vectors because of their integration into the 
chromosomes of the cell. However, integration 
into undesirable sites has hampered their 
development; for example Moloney-murine 
leukaemia virus (Mo-MLV)-based vectors have 
integrated into unintended genomic sites that 
led to oncogene activation in a number of cases 
(reviewed in Serrao & Engelman 2016).
The ability of lentiviruses to infect and 
replicate in quiescent cells has made them 
attractive candidates for gene therapy vectors. 
However, it would be desirable to be able to 
redirect integration away from active genes. 
One of the determinants of integration targeting 
of lentiviruses is a host factor termed LEDGF/
p75, which is a lentiviral integrase-binding 
protein that tethers viral DNA integration to 
transcriptionally active regions of the host 
genome (Cherepanov 2007, Hare et al. 2009). 
However, there is evidence to suggest that 
LEDGF/p75 is not the only host factor directing 
lentiviral integrase to actively transcribed sites 
in the genome, and the viral capsid and CA-
binding host proteins seem also to play a role 
(rewieved by Serrao & Engelman 2016).  
Host defences
Infection by retroviruses is controlled at several 
levels; these include innate immunity and 
intrinsic cellular restriction as a first line of 
defence, and then adaptive immunity. The virus 
has to overcome all these hurdles in order to 
successfully infect the host.
During the last decade or so, a number of 
anti-retrovirus restriction factors have been 
discovered, which the viruses have in turn 
developed countermeasures for, each in their 
respective host.  Most of these restriction factors 
have been discovered by studying the viral 
countermeasures, like the lentiviral accessory 
proteins Vif, Vpu, Vpx/Vpr (reviewed in Jia et 
al. 2015,  Simon et al. 2015).  
The APOBEC3 (apolipoprotein B mRNA-
editing catalytic polypeptide-like 3) proteins are 
one example of these host-encoded retrovirus 
restriction factors. They catalyse the deamination 
of cytosine to uracil in the minus-strand of viral 
DNA during reverse transcription, resulting 
in G-to-A mutation in the plus-strand (Harris 
et al. 2003, Mangeat et al. 2003, Zhang et al. 
2003). The resulting uracil residues can lead to 
functional inactivation of the retrovirus either 
by hypermutation or by triggering degradation 
of the viral nucleic acid prior to integration. 
The incorporated uracils might also impede the 
reverse transcriptase (Adolph et al. 2013). The 
APOBEC3 proteins vary in number between 
species; the mouse has one gene, humans have 
seven, and sheep and cows are in between with 
three APOBEC3 genes coding for four proteins 
(Jonsson et al. 2006, LaRue et al. 2010, 2008, 
2009,  Sheehy et al. 2002). The seven primate 
APOBEC3 proteins are commonly called 
APOBEC3A through APOBEC3H, but a 
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nomenclature system based on the Z-domains 
(cytosine deaminase motifs) has been proposed 
for the non-primate APOBEC3 genes (LaRue et 
al. 2008, 2009)
Most lentiviruses including MVV and 
HIV encode a counter-defence protein, Vif, 
which is essential for virus replication in 
natural target cells and in vivo (Audoly et al. 
1992,  Fisher et al. 1987, Kristbjornsdottir et 
al. 2004, Strebel et al. 1987). The Vif proteins 
are potent APOBEC3 antagonists; all human 
APOBEC3 proteins except APOBEC3A and 
APOBEC3B are sensitive to HIV-1 Vif, and 
sheep APOBEC3Z2-Z3 and APOBEC3Z3 are 
sensitive to MVV Vif (Hultquist et al. 2011, 
Jonsson et al. 2006, Larue et al. 2010, Refsland 
et al. 2010). However, sheep APOBEC3Z1 
has been shown to be analogous to human 
APOBEC3A and is not sensitive to MVV Vif 
(de Pablo-Maiso et al. 2017). Vif induces 
polyubiquitylation of APOBEC3 for subsequent 
degradation in the proteasome, thus preventing 
the incorporation of APOBEC3 into the viral 
particle (Conticello et al. 2003,  Mariani et 
al. 2003, Sheehy et al. 2003, Yu et al. 2003). 
HIV-1 Vif achieves this by acting as an 
adaptor connecting APOBEC3 and the cullin5-
ElonginB-ElonginC-RBX2 ubiquitin ligase (Yu 
et al. 2003). The conserved T/SLQXLA motif in 
the C-terminus of Vif interacts with ElonginC 
and ElonginB and is referred to as the BC box 
(Yu et al. 2003, 2004). The cellular transcription 
factor core-binding factor-beta (CBFβ) is 
required for HIV-1 Vif mediated degradation 
of human APOBEC3 (Jager et al. 2012, Zhang 
et al. 2012). CBFβ forms a complex with Vif 
which facilitates the assembly of a functional 
APOBEC3 ubiquitin ligase complex (Hultquist 
et al. 2012, Kim et al. 2013). MVV and other 
SRLVs do not use CBFβ, but recruit Cyclophilin 
A (CypA) for stabilizing the APOBEC3-Vif-
ubiquitin ligase complex (Kane et al. 2015).
We have obtained evidence to suggest that 
neutralizing APOBEC3 is not the sole function 
of MVV Vif. An MVV mutant with simultaneous 
mutations in the capsid (CA) and Vif has a pro-
ser mutation in the C-terminus of MVV Vif 
together with a leu- arg substitution in CA. 
This mutant is attenuated in viral replication in 
blood-derived macrophages and in vivo without 
inducing hypermutation. These mutations may 
define a novel restriction factor that targets the 
CA and is counteracted by Vif (Franzdottir et al. 
2016, Gudmundsson et al. 2005).
CypA is a peptidyl-prolyl isomerase that 
binds to the capsid of some lentiviruses, 
including HIV-1, but not to MVV capsid or 
to some other lentiviruses such as SIVmac or 
EIAV (Kane et al. 2015, Lin & Emerman 2006). 
CypA is thought to influence the recognition 
of CA by host factors that may act at the time 
of reverse transcription, nuclear import or 
integration (reviewed in Strebel et al. 2009). 
CypA promotes reverse transcription of HIV-
1, but reduces nuclear entry in a cell-specific 
manner. It has been speculated that there may 
exist a cell-type specific CypA-dependent 
restriction factor that blocks HIV-1 replication 
by delaying CA core uncoating and hindering 
nuclear entry (De Iaco & Luban 2014). The 
interaction of CypA with HIV-1 capsid has 
been found to be essential for the virus to evade 
detection by the innate immune sensor cGAS 
and to avoid subsequent activation of the innate 
immune response (Rasaiyaah et al. 2013). CypA 
has also been shown to interact with HIV-1 
Vpr (Zander et al. 2003). Furthermore, a CypA 
imposed inhibition of SIV in human cells is 
counteracted by Vif (Takeuchi et al. 2007). It 
is clear that CypA affects both replication and 
restriction of the lentiviruses in various ways.
One of the host factors affected by CypA is 
TRIM5α. There are almost 100 genes encoding 
TRIM proteins in the human genome, and some 
of these show anti-viral activity (Stremlau et 
al. 2004, reviewed in Grutter & Luban 2012). 
TRIM5α binds to the incoming cores of HIV-1 
and is thought to trigger premature uncoating. 
However, the mechanism of this inhibition is 
not completely understood. Some studies have 
found that TRIM5α can block HIV-1 at more 
than one step, both at reverse transcription and 
nuclear import (Yap et al. 2006). Recognition of 
the capsid lattice by TRIM5α also induces an 
innate immune response against the virus (Pertel 
et al. 2011), and recently, TRIM5α was found 
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to regulate autophagy (Mandell et al. 2014). A 
functional TRIM5α protein in sheep has been 
reported and shown to inhibit MVV (Jauregui 
et al. 2012). 
Additional host factors that have been found 
in recent years to restrict HIV are SAMHD1, 
BST2/tetherin and MxB. The effect of these 
host factors on SRLV replication has yet not 
been reported.
SAMHD1 causes inefficient replication of 
HIV-1 and other lentiviruses in macrophages 
and dendritic cells, but is antagonized by the 
viral protein Vpx which targets the protein for 
proteasomal degradation (Hrecka et al. 2011, 
Laguette et al. 2011). Vpx is present in HIV-2 
and several SIVs but not in HIV-1. SAMHD1 
is a dNTPase and is thought to inhibit HIV-
1 by limiting the dNTP pool in non-dividing 
cells and thus inhibiting viral c-DNA synthesis 
(Goldstone et al. 2011).  However, whether 
lowering cellular dNTP levels is the sole 
mechanism of restriction is not clear (Welbourn 
& Strebel 2016). 
BST-2/tetherin inhibits virus replication 
by “tethering” the viral particles to the cell at 
budding, thus preventing their release (Hinz 
et al. 2010). BST-2/tetherin is antagonized by 
the viral protein Vpu (Neil et al. 2008), which 
is encoded by HIV-1 and a few SIVs, but 
not by HIV-2 and most SIVs or non-primate 
lentiviruses.
Mx2/B is an interferon induced host factor 
that potently inhibits HIV-1 replication at a post-
reverse transcription stage (Goujon et al. 2013). 
MxB primarily targets the capsid and inhibits 
PIC nuclear import and integration (Matreyek 
et al. 2014).  
Adaptive immunity
MVV elicits both humoral and cell-mediated 
immune responses in the host (Griffin et al. 1978, 
Larsen et al. 1982, Sihvonen 1981, Thormar & 
Helgadottir 1965, Torsteinsdottir et al. 1992). 
There seem to be host-related differences in the 
strength of the immune response.  Whereas the 
Icelandic sheep elicit a strong neutralization 
response against the MVV strains circulating in 
Iceland at the time of the epizootic, neutralizing 
antibodies are absent or of a very low titre in 
many MVV and CAEV infections (Cheevers et 
al. 1993, Klevjer-Anderson & McGuire 1982, 
McGuire et al. 1990, Narayan et al. 1984). In 
experimental MVV infection, type-specific 
neutralizing antibodies are detected 6 weeks 
to 4 months post infection, and other more 
broadly neutralizing antibodies appear up to 4 
years later in most sheep (Andresdottir et al. 
2002, Petursson et al. 1976). A type-specific 
neutralization epitope has been mapped in the 
fourth variable region (V4) of the MVV SU and 
was shown to be immunodominant and thus 
is termed the “principal neutralizing domain 
(PND)” by analogy to the V3 loop in HIV-1 
Env (Haflidadottir et al. 2008,  Javaherian et al. 
1989,  Skraban et al. 1999).  We have shown 
that neutralizing antibody is effective in MVV 
infection in vivo (Andresdottir et al. 2002, 
Arnarson et al. 2017) and neutralizing antibodies 
have been shown to have some protective effect 
in the cerebrospinal fluid, where they are locally 
produced (Georgsson et al. 1993, Petursson 
et al. 1976). A similar pattern of neutralizing 
antibody development has been reported in HIV 
infection (Albert et al. 1990, Rusert et al. 2016).
The role of cellular immunity in HIV-1 
infection has been well documented. Several 
lines of evidence suggest that CD8+ T-cells 
play a significant role in protection from HIV 
replication and disease progression; the initial 
control of viremia in HIV infection coincides 
with an expansion of HIV-1-specific CD8+ 
T-cells (Borrow et al. 1994, Koup et al. 1994), 
there is selection for escape mutants from the 
cytotoxic T-lymphocyte response (Goulder 
& Watkins 2004) and HIV non-progressors 
preferentially maintain highly functional HIV-
specific CD8+ T-cells (Betts et al. 2006). Virus 
specific CD8+ T-cells have been demonstrated 
after in vitro stimulation of lymphocytes from 
MVV and CAEV infected sheep and goats, and 
escape variants from the cytotoxic response 
have been detected (Blacklaws et al. 1994, Lee 
et al. 1994, Lichtensteiger et al. 1993). 
Despite active immune responses, neither 
HIV nor MVV are cleared from the host. 
Several lines of evidence have shown that 
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pathogenesis of these viral diseases is immune-
mediated. Thus, early lesions in experimental 
MVV infection of sheep were almost abolished 
by immunosuppressive treatment with 
antithymocyte serum and cyclophosphamide 
(Nathanson et al. 1976). Very few cells in the 
brain are productively infected (Haase 1986) 
and it is likely that lesions are in large part due 
to amplification of the immune response to viral 
antigens with a great influx of macrophages and 
lymphocytes and secretion of cytokines resulting 
in non-specific tissue damage (Georgsson et al. 
1989, Pétursson et al. 1992). For comparison 
of MVV and HIV pathology see Blacklaws 
and Harkiss (2010),  Georgsson (1994),  and 
Thormar (2005).
Persistence
The persistence of MVV in the face of a strong 
immune response was an unsolved puzzle for a 
long time. Sigurdsson proposed that “perhaps 
the infectious agent is so well adapted to the 
host, so well camouflaged, that it has to some 
extent eliminated its own species specificity in 
the immunological sense” (Sigurdsson 1954b). 
One way for lentiviruses to escape the immune 
response may be through antigenic drift, as 
proposed by Gudnadottir (Gudnadottir 1974) 
and further confirmed and extended by Narayan 
et al. (Narayan et al. 1977, 1978, 1981). A wealth 
of genetic, immunological and structural studies 
of HIV-1 envelope glycoproteins have revealed 
remarkable diversity and conformational 
flexibility of these molecules that may result 
in neutralization escape, either by mutation 
of the neutralization epitopes or indirectly 
by conformational masking of epitopes or 
shielding by glycosylation (Huang et al. 2005, 
Kwong et al. 2002, Wei et al. 2003, Wyatt & 
Sodroski 1998, Wyatt et al. 1998). However, 
antigenic escape cannot be the only means of 
persistence, since virus that had not evolved 
at all was repeatedly isolated from sheep up to 
10 years after MVV infection (Arnarson et al. 
2017, Lutley et al. 1983). It has been suggested 
that hematopoietic stem cells in the bone 
marrow serve as a latent reservoir (Gendelman 
et al. 1985); this may not be the only reservoir, 
however, since a study of long-term CAEV 
infection in goats found infrequent infection 
of the bone marrow (Ravazzolo et al. 2006). 
Another possible reservoir is the spleen, which 
has been shown to be a monocyte reservoir 
(Swirski et al. 2009) and is a frequent site for 
virus isolation. We have obtained evidence to 
suggest that latently infected monocytes are shed 
into the blood stream from hidden reservoirs, 
where they are caught by the immune response. 
Virus that had been transmitted naturally via 
aerosol was shown to harbour mutations in the 
env gene that changed antigenicity, suggesting 
that the viruses have to escape the immune 
response of the host to allow them then to go 
on and infect other animals (Arnarson et al. 
2017). A similar pattern of persistence has been 
described for HIV, i.e. antigenic escape and 
latency. The latent reservoirs for HIV-1 have not 
been fully elucidated, but it has been shown that 
resting CD4+ T cells harbour integrated viral 
genomes and constitute one reservoir of latency 
(Descours 2017, reviewed by Eisele & Siliciano 
2012, van der Sluis et al. 2013). However, it 
has been suggested that macrophages constitute 
another virus reservoir (Alexaki & Wigdahl 
2008, Archin et al. 2014) and astrocytes, 
perivascular macrophages and microglial cells 
in the brain may be latently infected. All three 
cell types are long-lived with a half-life ranging 
from months to years (for microglial cells) 
(reviewed by Marban et al. 2016).  The brain 
has been proposed to be one site of latency for 
HIV and SIV (Alexaki & Wigdahl 2008, Avalos 
et al. 2017).  HIV enters the CNS early after 
infection and continues to cause HIV-associated 
neurocognitive disorders in approximately 50% 
of infected individuals despite antiretroviral 
therapy.
The mechanisms of latency have not been 
fully elucidated, but it is commonly assumed 
that after integration, latent infection is 
established through chromosome modification 
either by the absence of necessary transcription 
factors or by the presence of repressors acting 
on the LTR.  AP-1 and AP-4 binding sites in the 
LTR of HIV-1 have been found important in the 
establishment of latency (Duverger et al. 2013, 
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Imai & Okamoto 2006). In this connection it 
is interesting to note that most MVV strains 
harbour AP-1 binding sequences in the LTR and 
an AP-4 motif is the best conserved element in 
the SRLV LTR (Gomez-Lucia et al. 2014,  Hess 
et al. 1989, Sargan et al. 1995).
Concluding remarks
Although HIV has been extensively studied 
for the last 35 years or so, a number of open 
questions still remain to be answered. Among 
these are the sites and mechanisms of latency; 
host- and virus-encoded proteins that take 
part in reverse transcription, nuclear entry 
and integration; the mechanisms of restriction 
by host-encoded restriction factors and the 
mechanisms of virus counter-defence; the role 
of the immune system in pathogenesis; invasion 
and replication of virus in the brain, and more. 
Some of these questions can be explored in 
the non-primate lentiviral systems like MVV/
sheep. The main difference between the primate 
lentiviruses and the SRLVs is that the SRLVs 
do not infect T lymphocytes and therefore do 
not cause overt immunodeficiency. However, a 
number of features are highly conserved between 
the lentiviruses, like the enzyme integrase 
whose depiction in MVV has helped clarify the 
structure of HIV-1 integrase. The two accessory 
genes that are common to HIV and MVV, Vpr 
and Vif, may have conserved functions some of 
which have yet to be elucidated; does Vpr have 
a role in latency and does Vif have additional 
functions besides neutralizing APOBEC3? 
What is the role of cyclophilin in infection? 
Does cyclophilin bound to Vif in MVV have the 
same role as cyclophilin bound to CA in HIV-1? 
Cells in the CNS are infected by macrophage-
tropic HIV and constitute a latent reservoir. It is 
likely that MVV can serve as a model for CNS 
infection. Other functions may be carried out 
differently by the different lentiviruses and these 
differences may also be informative.  
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